TABLE 2

ORs of group analyses

Group and ReferencePatients, nAny-stage ROPStage 3 or 4, surgical ROP
nOR (95% Cl)nOR (95% Cl)
Exclusive human milk versus any formula
 Hylander et al, 20012117 vs 1576/820.50 (0.18–1.42)0/150.26 (0.02–4.58)
 Manzoni et al, 201317314 vs 18411/290.19 (0.09–0.40)4/220.10 (0.03–0.28)
Mainly human milk versus mainly formula
 Hylander et al, 20012145 vs 9019/530.51 (0.25–1.05)0/110.08 (0.00–1.32)
 Furman et al, 20032232 vs 8714/450.73 (0.32–1.64)No data
 Maayan-Metzger et al, 201223188 vs 17223/220.95 (0.51–1.78)3/70.38 (0.10–1.50)
 Manzoni et al, 201317314 vs 18411/290.19 (0.09–0.40)4/220.10 (0.03–0.28)
Any human milk versus exclusive formula
 Hylander et al, 200121100 vs 7441/470.40 (0.22–0.74)6/90.46 (0.16–1.36)
 Furman et al, 20032279 vs 4044/152.10 (0.96–4.57)No data
 Heller et al, 200718788 vs 269No data130/331.41 (0.94–2.13)
 Manzoni et al, 201317314 vs 18411/290.19 (0.09–0.40)4/220.10 (0.03–0.28)
Exclusive human milk versus exclusive formula
 Hylander et al, 20012117 vs 746/470.40 (0.22–0.74)0/90.20 (0.01–3.55)
 Manzoni et al, 201317314 vs 18411/290.19 (0.09–0.40)4/220.10 (0.03–0.28)